Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma ML Wang, S Rule, P Martin, A Goy, R Auer, BS Kahl, W Jurczak, ... New England Journal of Medicine 369 (6), 507-516, 2013 | 1915 | 2013 |
Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas TA Knijnenburg, L Wang, MT Zimmermann, N Chambwe, GF Gao, ... Cell reports 23 (1), 239-254. e6, 2018 | 970 | 2018 |
Integrated proteogenomic characterization of human high-grade serous ovarian cancer H Zhang, T Liu, Z Zhang, SH Payne, B Zhang, JE McDermott, JY Zhou, ... Cell 166 (3), 755-765, 2016 | 953 | 2016 |
Proteogenomic analysis of human colon cancer reveals new therapeutic opportunities S Vasaikar, C Huang, X Wang, VA Petyuk, SR Savage, B Wen, Y Dou, ... Cell 177 (4), 1035-1049. e19, 2019 | 619 | 2019 |
Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma MA Gillette, S Satpathy, S Cao, SM Dhanasekaran, SV Vasaikar, K Krug, ... Cell 182 (1), 200-225. e35, 2020 | 523 | 2020 |
Synthesis and heavy metal immobilization behaviors of slag based geopolymer Z Yunsheng, S Wei, C Qianli, C Lin Journal of hazardous materials 143 (1-2), 206-213, 2007 | 513 | 2007 |
Integrated proteogenomic characterization of clear cell renal cell carcinoma DJ Clark, SM Dhanasekaran, F Petralia, J Pan, X Song, Y Hu, ... Cell 179 (4), 964-983. e31, 2019 | 497 | 2019 |
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results ML Wang, KA Blum, P Martin, A Goy, R Auer, BS Kahl, W Jurczak, ... Blood, The Journal of the American Society of Hematology 126 (6), 739-745, 2015 | 475 | 2015 |
Proteogenomic and metabolomic characterization of human glioblastoma LB Wang, A Karpova, MA Gritsenko, JE Kyle, S Cao, Y Li, D Rykunov, ... Cancer cell 39 (4), 509-528. e20, 2021 | 450 | 2021 |
Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography–mass spectrometry P Mertins, LC Tang, K Krug, DJ Clark, MA Gritsenko, L Chen, KR Clauser, ... Nature protocols 13 (7), 1632-1661, 2018 | 426 | 2018 |
Composition design and microstructural characterization of calcined kaolin-based geopolymer cement Z Yunsheng, S Wei, L Zongjin Applied Clay Science 47 (3-4), 271-275, 2010 | 388 | 2010 |
Interaction between sulfate and chloride solution attack of concretes with and without fly ash J Zuquan, S Wei, Z Yunsheng, J Jinyang, L Jianzhong Cement and Concrete Research 37 (8), 1223-1232, 2007 | 381 | 2007 |
Proteogenomic characterization of endometrial carcinoma Y Dou, EA Kawaler, DC Zhou, MA Gritsenko, C Huang, L Blumenberg, ... Cell 180 (4), 729-748. e26, 2020 | 361 | 2020 |
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial M Wang, L Fayad, N Wagner-Bartak, L Zhang, F Hagemeister, ... The lancet oncology 13 (7), 716-723, 2012 | 356 | 2012 |
Development of sustainable cementitious materials Z Li, Z Ding, Y Zhang Proceedings of international workshop on sustainable development and …, 2004 | 348 | 2004 |
Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug–induced apoptosis Y Zheng, Z Cai, S Wang, X Zhang, J Qian, S Hong, H Li, M Wang, J Yang, ... Blood, The Journal of the American Society of Hematology 114 (17), 3625-3628, 2009 | 341 | 2009 |
Preparation of C200 green reactive powder concrete and its static–dynamic behaviors Z Yunsheng, S Wei, L Sifeng, J Chujie, L Jianzhong Cement and Concrete Composites 30 (9), 831-838, 2008 | 307 | 2008 |
Characterization and simulation of microstructure and thermal properties of foamed concrete S Wei, C Yiqiang, Z Yunsheng, MR Jones Construction and building materials 47, 1278-1291, 2013 | 283 | 2013 |
Impact properties of geopolymer based extrudates incorporated with fly ash and PVA short fiber Z Yunsheng, S Wei, L Zongjin, Z Xiangming, C Chungkong Construction and Building Materials 22 (3), 370-383, 2008 | 275 | 2008 |
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial M Wang, N Fowler, N Wagner-Bartak, L Feng, J Romaguera, SS Neelapu, ... Leukemia 27 (9), 1902-1909, 2013 | 249 | 2013 |